Effects of FT011 in Systemic Sclerosis

• Status: Recruiting
• Trial end date: 2022-04-01

Summary

FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).

• Phase: Phase 2

Details

• Lead Sponsor: Certa Therapeutics